The hunt for a hep B cure heats up, as Antios Therapeutics preps for an IPO
While hepatitis B virus (HBV) infection is avoidable with a vaccine, a host of companies are searching for a cure for the hundreds of thousands in the US who already have it. Antios Therapeutics threw its hat in the ring three years ago, and on Monday closed a $96 million crossover round to see its lead program through Phase II.
When asked if an IPO is on the horizon, CEO Greg Mayes said: “We’re going to be prepared for one, yes.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.